<DOC>
	<DOC>NCT02489331</DOC>
	<brief_summary>Post marketing surveillance of safety and efficacy for Cholib in Korean patients under the "New Drug Re-examination"</brief_summary>
	<brief_title>Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".</brief_title>
	<detailed_description>The objective of this surveillance is to identify problems and questions on Cholib® and on the following matters under the condition that the investigational product is in use. 1. Serious adverse event and adverse drug reaction profile - Death or a life-threatening condition - Hospitalization or prolonged hospitalization - Persistent or significant disability/incapacity - Congenital anomaly/birth defect - Other medically significant events 2. Unexpected adverse event/adverse drug reaction profile 3. Known adverse drug reaction profile 4. Non-serious adverse drug reaction profile 5. Other information related to the product safety 6. Efficacy evaluation 7. Study of extended follow-up Surveillance of the safety and efficacy of the subjects who received Cholib® for long-term use at least 24 weeks. 8. Study of special patient Analysis of specific patients such as elderly patients (65 years and above), patients with renal/hepatic disease</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Clinical diagnosis of mixed dyslipidaemia who has high triglycerides and low HDL cholesterol level while LDL cholesterol levels are adequately controlled with the corresponding dose of simvastatin monotherapy Patients who are hypersensitive (allergic) to peanuts, soybean or any of the ingredients of the medicine Patients who experienced photoallergy or phototoxic reactions during treatment with fibrates or ketoprofen Patients who have active hepatic disorder or have serum transaminase increased continuously without identified reason Patients who have gallbladder disease Patients who have chronic or acute pancreatitis except acute pancreatitis due to severe hypertriglyceridemia Patients who have moderately or severely reduced kidney function(estimated glomerular filtration rate &lt; 60mL/min/1.73m2) Cholib® administration combined administration with fibrates, statins, danazol, cyclosporine or strong cytochrome P450(CYP)3A4 inhibitor 145/40mg Cholib® Combined administration with amiodarone, verapamil, amlodipine or diltiazem Children &lt;19 years Pregnant or breastfeeding women Patients with biliary cirrhosis Patients who have myopathy and/or previously had rhabdomyolysis or myopathy while taking statins and/or fibrates or had 5 times more creatine phosphokinase than Upper limit of Normal (ULN) while taking statins previously Patients who have rare hereditary problems with lactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption since this drug contains lactose Patients who have rare hereditary problems with fructose intolerance, glucosegalactose malabsorption or sucraseisomaltase deficiency since this drug contains sucrose Patients who have LDL Cholesterol ≥130 mg/dL and triglyceride &lt; 150mg/dL and HDL cholesterol ≥60mg/dL Investigators will refer to the product market authorization (label) for inclusion/exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dyslipidemias</keyword>
</DOC>